

Table S1. High immunohistochemical expression (> cut-off) among subtypes: Training and Validation cohort.

Training cohort					
	Mesothelin	Claudin-15	CFB	PAI1	PAK4
Training cohort (n=73)	37 (50.7%)	26 (35.6%)	25 (32.2%)	46 (63%)	54 (74%)
ES (n=31)	31 (100%)	21 (67.7%)	18 (58.1%)	11 (35.5%)	18 (58.1%)
BS (n=25)	6 (24%)	3 (12%)	7 (28%)	20 (80%)	23 (92%)
SS (n=17)	0 (0%)	2 (11.8%)	0 (0%)	15 (88.2%)	13 (76.5%)
Validation cohort					
	Mesothelin	Claudin-15	CFB	PAI1	PAK4
Validation cohort (n=30)	14 (46.7%)	11 (36.7%)	9 (30%)	20 (66.7%)	23 (76.7%)
ES (n=11)	10 (90.9%)	8 (72.7%)	7 (63.6%)	8 (72.7%)	7 (63.6%)
BS (n=11)	4 (36.4%)	3 (27.3%)	2 (18.2%)	6 (54.5%)	10 (90.9%)
SS (n=8)	0 (0%)	0 (0%)	0 (0%)	6 (75%)	6 (75%)

ES: epithelioid subtype; BS: biphasic subtype; SS: sarcomatoid subtype; CFB: Complement factor B; PAI1: Plasminogen activator inhibitor 1, PAK4: p21-activated kinase 4.